Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.

< BACK TO ARCHIVE


2022 Sep 12


J Allergy Clin Immunol Pract


http://www.ncbi.nlm.nih.gov/pubmed/36108923?dopt=Abstract

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.

Authors

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C
J Allergy Clin Immunol Pract. 2022 Sep 12.
PMID: 36108923.

Abstract

Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies.
Read This Paper